NCT06953505 At Home Ammonia Monitoring of Inborn Errors of Ammonia Metabolism
| NCT ID | NCT06953505 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sequitur Health Corp. |
| Condition | Urea Cycle Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-09-23 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-09-23 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn if people with certain ammonia metabolism disorders will measure their ammonia levels at home. The main question it aims to answer is: • Will participants measure their ammonia every day? Participants will be asked to: * Attend two in-person study visits at the clinic. * Measure temperature, heart rate, and blood oxygen every day. * Complete a short survey every day. * Measure ammonia every day.
Eligibility Criteria
Inclusion Criteria: * Confirmed ammonia disorder such as * Ornithine transcarbamylase deficiency * Systemic primary carnitine deficiency * Type I citrullinemia * Argininosuccinic aciduria * Isolated methylmalonic acidemia * Type II citrullinemia * Propionic acidemia * Isovaleric acidemia * Multiple acyl-CoA dehydrogenase deficiency * Pyruvate carboxylase deficiency * Argininemia (arginase deficiency) * Carbamoyl phosphate synthase I deficiency * Dihydrolipoamide dehydrogenase deficiency * Lysinuric protein intolerance * Hyperornithinemia-hyperammonemia-homocitrullinuria * Carnitine-acylcarnitine translocase deficiency * Carbonic anhydrase VA deficiency * N-acetyl glutamate synthetase deficiency * English Literacy Exclusion Criteria: * Incarcerated * Presence of a non-inborn error of metabolism medical condition associated with abnormal ammonia metabolism (e.g., end stage liver disease). * Unable to read in English
Contact & Investigator
Marylaura L Thomas, Ph.D.
PRINCIPAL INVESTIGATOR
Sequitur Health Corp.
Frequently Asked Questions
Who can join the NCT06953505 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Urea Cycle Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06953505 currently recruiting?
Yes, NCT06953505 is actively recruiting participants. Contact the research team at info@sequiturhealth.com for enrollment information.
Where is the NCT06953505 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT06953505 clinical trial?
NCT06953505 is sponsored by Sequitur Health Corp.. The principal investigator is Marylaura L Thomas, Ph.D. at Sequitur Health Corp.. The trial plans to enroll 30 participants.